$XON News

Last published 2y ago

2y agoBMY DRIO NVS OSTX+1OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of DirectorsBusiness WireConcurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate
4y agoCSX PESI XONBiotech Company Allonnia Appoints Lieutenant General (Ret.) Thomas P. Bostick to Board of Directors; Celebrates Additions to Advisory TeamBusiness WireAllonnia brings on advisors for Finance, Human Resources and Marketing as they continue growth and commercialization Allonnia, the bio-ingenuity company dedicated to extracting value where others see waste, today announces the appointment of Lieutena
6y agoPLUG LIN HII RTX+8Cramer's lightning round: Plug Power versus LindeCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
6y agoPESI XON PGENPerma-Fix Appoints Lieutenant General (Ret.) Thomas P. Bostick to Board of DirectorsACCESS NewswireFormer Army Chief of Engineers and Commanding General of US Army Corps of Engineers
6y agoXONNew patent application published for: Crystalline Diacylhydrazine and the Use ThereofUS Patent Applications (USPTO)( 1 of 1 )
6y agoXONTriple-Gene Announces Presentation at Upcoming Biotech Showcase Investor ConferencePR NewswireTriple-Gene LLC, a clinical stage cardiovascular gene therapy company, today announced that Thomas D. Reed, PhD, Co-Founder, will present at the...
6y agoXONPrecigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML)PR NewswirePrecigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of...
6y agoDAR XONDarling Ingredients Acquires 100% of EnviroFlightPR NewswireDarling Ingredients Inc. (NYSE: DAR), today announced that it has acquired the 50% joint venture interest of EnviroFlight, LLC owned by Intrexon...
6y agoXONIntrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare FocusPR NewswireIntrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the...
6y agoXONOragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral MucositisBusiness WireTAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, an easy to use oral rinsing system designed to pr ...
6y agoXONTriple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual MeetingPR NewswireTriple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), yesterday...
7y agoXONIntrexon Corp (XON) CEO RJ Kirk on Precigen Inc Business and Pipeline Update Conference Call (Transcript)Earnings Call Transcripts
7y agoXON PTCT FCSC AQBIntrexon Reports Third Quarter 2019 Financial ResultsPR NewswireIntrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the...
7y agoXONTriple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart FailurePR NewswireTriple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today...
7y agoXONIntrexon to Announce Third Quarter Financial Results on November 12thPR NewswireIntrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the...
7y agoXONDavid H. Witte to lead MBP Titan LLCPR NewswireIntrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the...
7y agoXONActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of GlutenPR NewswireActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) and innovative clinical-stage biotechnology company...
7y agoXONIntrexon Reports Second Quarter and First Half 2019 Financial ResultsPR NewswireIntrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the...
7y agoXONPrecigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerPR NewswirePrecigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of...
7y agoXONIntrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8thPR NewswireIntrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the...
7y agoXONActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 DiabetesPR NewswireActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) and innovative clinical-stage biotechnology company...
7y agoXONPrecigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)PR NewswirePrecigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of...
7y agoXONIntrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid ProductionPR NewswireIntrexon Corporation (Intrexon) (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve quality of life and health of...
7y agoXONIntrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences ConferencePR NewswireIntrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the...
7y agoXONIntrexon Corp (XON) Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
8y agoXONIntrexon Corp (XON) CEO Randal Kirk on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoXONIntrexon's (XON) CEO Randal Kirk on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoJMP XON HCAPJMP Group Announces Closing of Harvest Intrexon Enterprise FundBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--JMP Group LLC (NYSE:JMP), an investment banking and alternative asset management firm, announced today that Harvest Capital Strategies has raised $245 million for the Harvest Intrexon Enterprise Fund, an investment vehicle dedicated to funding companies that utilize the inventions, discoveries and technologies of Intrexon Corporation (NYSE: XON), a leader in synthet ...
12y agoFCSC XONFibrocell Science to Present at 2014 Stem Cell Meeting on the MesaBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that John Maslowski, vice president, scientific affairs of Fibrocell Science will present on Tuesday, October 7 at 2:30 p.m. PDT at the 4th Annu ...
12y agoFCSC XONFibrocell Science to Present at BioCentury NewsMakers of the Biotech Industry ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science will present at the BioCentury NewsMakers in the Biotech Industry ...
12y agoFCSC XONFibrocell Science and Intrexon Advance GM-HDF-COL7 toward Clinical Development for the Treatment of Recessive Dystrophic Epidermolysis BullosaBusiness WireEXTON, Pa. & GERMANTOWN, Md.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced plans to file an investigational new drug (IND) application with the U.S. Food ...
12y agoFCSC XONFibrocell Science Hosting R&D Day on September 24, 2014Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will host an R&D Day in New York on September 24, 2014. Presentations by key opinion leaders will include the Company’s lead orphan disea ...
12y agoFCSC XONFibrocell Science, Inc. to Move Stock Listing to NASDAQBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will transfer its U.S. stock exchange listing from the NYSE MKT to The NASDAQ Capital Market. The Company expects its securities to cea ...
12y agoFCSC NBS XONFibrocell Science Reports Second Quarter and First Half 2014 Financial and Operating ResultsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the second quarter and first half of 2014. The company will host a conference call and webcast today at 8:30 a.m. EDT.
12y agoFCSC XONFibrocell Science to Present at Wedbush 2014 Life Sciences Management Access ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, of Fibrocell Sci ...
12y agoFCSC XONFibrocell Science to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on August 11, 2014Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report second quarter and first half 2014 financial and operating results on August 11, 2014. David Pernock, chairman and chief ex ...
12y agoFCSC XONFibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy GroupBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it will present at the 2014 Patient Care Conference of the Dystrophic Epidermolysis Bullosa Research Association of America (De ...
12y agoFCSC XONFIbrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell TherapiesBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it has entered into an exclusive license agreement with The Regents of the University of California. Under the agreement, Fibro ...
12y agoFCSC XONFibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its genetically-modified autologous human fi ...
12y agoFCSC XONFibrocell Science to Present at Jefferies 2014 Global Healthcare ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, of Fib ...
12y agoFCSC NBS XONFibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEBBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), has been engaged by Fibrocell’s collaborator, Intrex ...
12y agoFCSC XONFibrocell Science Reports First Quarter 2014 Financial and Operating ResultsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the first quarter of 2014. The company will host a conference call and webcast at 5:00 p.m. EDT, today.
12y agoFCSC XONFibrocell Science to Report First Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on May 19, 2014Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report first quarter 2014 financial and operating results and provide an update on May 19, 2014. The update will include ...
12y agoFCSC XONFibrocell Science Announces Delay in Filing Quarterly Report on Form 10QBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that has filed a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission allowing for a five day ext ...
12y agoFCSC XONFibrocell Science to Present at 2nd Annual Regen Med Investor Day and BioCentury Future Leaders in the Biotech Industry ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science, will present at the Alliance for Regener ...
12y agoFCSC XONFibrocell Science Reports Fourth Quarter and Full Year 2013 Financial and Operating ResultsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 8:3 ...
12y agoFCSC XONFibrocell Science to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on March 17Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that it will report fourth quarter and full-year 2013 financial results and provide an update on the morning of March 17, 2014. The update will include its c ...
12y agoFCSC XONFibrocell Science to Present at Barclays Global Healthcare Conference 2014Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science (NYSEMKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science, will present at the Barclays Global Healthcare Conference 2014 at 2:30 pm EDT on Wedn ...
12y agoEPAM XONCorporate Leaders Receive Fourteenth Annual Emerald Asset Management “E-3 Awards”Business WireLEOLA, Pa.--(BUSINESS WIRE)--The Chief Executive and Chief Financial Officers of EPAM Systems (NYSE: EPAM) and the Chief Executive and Chief Science Officers of Intrexon Corp. (NYSE: XON) have been named as the recipients of the fourteenth annual “E-3 Awards,” presented by Emerald Asset Management at the 21st Annual Emerald Groundhog Day Investment Forum. The Forum was held in Philadelphia on Febr ...
12y agoFCSC XONFibrocell Science Appoints Robert Sheroff, Vice President of Technical OperationsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that Robert Sheroff has been appointed vice president of technical operations for the company. In this newly-created position, Mr. Sheroff will be responsibl ...